Ekso Bionics (NASDAQ:EKSO) Coverage Initiated by Analysts at StockNews.com

StockNews.com initiated coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a research report released on Wednesday. The brokerage issued a hold rating on the stock.

A number of other equities analysts also recently weighed in on the company. HC Wainwright reissued a “buy” rating and set a $9.00 price target on shares of Ekso Bionics in a research report on Tuesday, January 14th. Lake Street Capital dropped their target price on Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a report on Tuesday, October 29th.

Ekso Bionics Stock Up 1.6 %

EKSO stock opened at $0.64 on Wednesday. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.81 and a quick ratio of 2.14. The stock has a market capitalization of $14.15 million, a P/E ratio of -0.99 and a beta of 1.47. Ekso Bionics has a fifty-two week low of $0.50 and a fifty-two week high of $2.50. The business has a 50-day moving average of $0.67 and a 200-day moving average of $0.94.

Ekso Bionics (NASDAQ:EKSO) last posted its quarterly earnings data on Monday, October 28th. The company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.02). The business had revenue of $4.13 million for the quarter, compared to analyst estimates of $6.00 million. Ekso Bionics had a negative return on equity of 83.09% and a negative net margin of 62.95%. During the same quarter in the prior year, the company earned ($0.24) earnings per share. On average, sell-side analysts anticipate that Ekso Bionics will post -0.48 earnings per share for the current fiscal year.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.